[go: up one dir, main page]

WO2011109459A3 - Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases - Google Patents

Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases Download PDF

Info

Publication number
WO2011109459A3
WO2011109459A3 PCT/US2011/026778 US2011026778W WO2011109459A3 WO 2011109459 A3 WO2011109459 A3 WO 2011109459A3 US 2011026778 W US2011026778 W US 2011026778W WO 2011109459 A3 WO2011109459 A3 WO 2011109459A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
skin
compositions
kits
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/026778
Other languages
French (fr)
Other versions
WO2011109459A2 (en
Inventor
Robert W. Keane
Juan Pablo De Rivero Vaccari
Marty Eleanor Sawaya
W. Dalton Dietrich
Helen M. Bramlett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of WO2011109459A2 publication Critical patent/WO2011109459A2/en
Publication of WO2011109459A3 publication Critical patent/WO2011109459A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The methods and kits described herein can be used as diagnostic tools to assess if treatments have continuing therapeutic benefits in treating inflammatory skin diseases/disorders such as androgenetic alopecia (AGA) and a host of other skin problems, and for predicting male patiem baldness in a subject (e.g., human), Additionally, compositions and methods described herein can be used as treatments for inflammatory diseases of skin and hair (e.g., AGA) that are regulated by inflannnatory cytokines and inflammasomes. The experiments described herein show that the NLRPI inflammasome regulates inflammation in patients with skin and hair diseases.
PCT/US2011/026778 2010-03-04 2011-03-02 Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases Ceased WO2011109459A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31045110P 2010-03-04 2010-03-04
US61/310,451 2010-03-04

Publications (2)

Publication Number Publication Date
WO2011109459A2 WO2011109459A2 (en) 2011-09-09
WO2011109459A3 true WO2011109459A3 (en) 2011-11-10

Family

ID=44542811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/026778 Ceased WO2011109459A2 (en) 2010-03-04 2011-03-02 Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases

Country Status (1)

Country Link
WO (1) WO2011109459A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691518B2 (en) * 2010-09-24 2014-04-08 Global Life Science Partners Limited Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
US9588118B2 (en) 2010-09-24 2017-03-07 Follea International Devices for performing colorimetric assay with plucked human hair
EP3515470B1 (en) * 2016-09-21 2023-06-14 Agency for Science, Technology and Research Methods for predicting skin inflammation and determining cancer susceptibility
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183377A1 (en) * 1999-11-30 2002-12-05 Peter Elsner Use of melatonin for treating androgenetic and diffuse alopecia
US20090035362A1 (en) * 2007-07-31 2009-02-05 Shih Charles C Y Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss
US20090233954A1 (en) * 2008-03-12 2009-09-17 Goren Andy Ofer Methods and systems for prognosis of a patient's response to treatment of androgenetic skin disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183377A1 (en) * 1999-11-30 2002-12-05 Peter Elsner Use of melatonin for treating androgenetic and diffuse alopecia
US20090035362A1 (en) * 2007-07-31 2009-02-05 Shih Charles C Y Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss
US20090233954A1 (en) * 2008-03-12 2009-09-17 Goren Andy Ofer Methods and systems for prognosis of a patient's response to treatment of androgenetic skin disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAWAYA ET AL.: "Androgen responsive genes as they affect hair growth.", EUROPEAN JOUMAL OF DERMATOLOGY, vol. 11, 2001, pages 304 - 308, Retrieved from the Internet <URL:http://www.jle.com/eNrevues/medecine/ejd/e-docs/00/01/88/A1/article.md> [retrieved on 20110823] *

Also Published As

Publication number Publication date
WO2011109459A2 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
EP2358378A4 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
WO2012083132A3 (en) Diagnosis and treatments relating to th2 inhibition
PL2311454T3 (en) Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same
EP3270938A4 (en) Methods and compositions relating to microbial treatment and diagnosis of skin disorders
WO2012030984A3 (en) Skin compositions and methods of use thereof
WO2011085162A3 (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
PL3176156T3 (en) Alkylamidothiazoles, cosmetic and dermatological preparations containing them, and their use for the treatment and prophylaxis of unwanted pigmentation of the skin
WO2015009726A3 (en) Medical uses of cd38 agonists
BR112015010772A2 (en) topical rinse composition, use of a composition and method for treating or improving an individual&#39;s skin against acne
WO2009147201A3 (en) Anti-inflammatory agents
MX2016007760A (en) Use of alkylamidothiazoles in cosmetic or dermatological preparations for the prophylaxis or treatment of sensitive skin.
WO2012050831A3 (en) Combination treatment for dermatological conditions
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
WO2012047645A3 (en) Combination treatment for rosacea
WO2012116990A3 (en) Novel use
WO2011109459A3 (en) Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases
UA111520C2 (en) [1,2,4]triazolopyridine compounds and used thereof as phosphodiesterase inhibitors
MX2012013607A (en) Tamarind seed polysaccharide for use in the treatment of inflammatory diseases.
WO2009143064A3 (en) Rice bran extracts for inflammation and methods of use thereof
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
WO2015063613A3 (en) Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
EP3979899A4 (en) Compositions and methods for monitoring progression and regression of disease in patients in response to therapy
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
WO2014091146A3 (en) Cosmetic use of a carob seed extract as a slimming active agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11751250

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11751250

Country of ref document: EP

Kind code of ref document: A2